Literature DB >> 27541018

Association of Long-Term Atorvastatin with Escalated Stroke-Induced Neuroinflammation in Rats.

Leila Simani1, Nima Naderi2, Fariba Khodagholi1, Masoud Mehrpour3, Sanaz Nasoohi4.   

Abstract

Statins are widely used in high-risk patients to reduce the stroke incidence. However, little has been investigated about the impact of chronic pretreatment with statins on cerebral ischemic insult following defined arterial occlusion. To address this in experimental rats, in the present work, atorvastatin was orally dosed for 1 month to evaluate the outcomes of the subsequent occlusive stroke induced by middle cerebral artery occlusion (MCAO). Our data was suggestive of potential escalating impact of chronic atorvastatin (Atv; 10 mg/kg) on neurological function, but not infarct volume. According to our immunoblotting data, such escalations were consistent with the prominent rise in TNF-α and IL-6 which paralleled with augmented Bax/Bcl2 ratio and Caspase-9 activation; however, these were not enough to worsen acute neurodegeneration determined by Fluoro Jade B staining. Noteworthy, such deteriorating effects were also partly detected in non-ischemic animals. Conclusively, our data are indicative of cerebral proinflammatory effects of chronic Atv which might overwhelm the beneficial pliotropic of the drug and predispose animals' brain to ischemic insult. Further studies on different statins with discrete pharmacokinetic properties are highly suggested to precisely explore stroke outcomes following long term prophylactic treatment particularly in primates.

Entities:  

Keywords:  Atorvastatin; Cerebral ischemia; Neuroinflammation

Mesh:

Substances:

Year:  2016        PMID: 27541018     DOI: 10.1007/s12031-016-0814-8

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  66 in total

1.  Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors.

Authors:  P A Kiener; P M Davis; J L Murray; S Youssef; B M Rankin; M Kowala
Journal:  Int Immunopharmacol       Date:  2001-01       Impact factor: 4.932

Review 2.  Coenzyme Q10 and statins: biochemical and clinical implications.

Authors:  Gian Paolo Littarru; Peter Langsjoen
Journal:  Mitochondrion       Date:  2007-03-27       Impact factor: 4.160

3.  Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia.

Authors:  Minoru Asahi; Zhihong Huang; Sunu Thomas; Shin-ichi Yoshimura; Toshihisa Sumii; Tatsuro Mori; Jianhua Qiu; Sepideh Amin-Hanjani; Paul L Huang; James K Liao; Eng H Lo; Michael A Moskowitz
Journal:  J Cereb Blood Flow Metab       Date:  2005-06       Impact factor: 6.200

4.  HMG CoA reductase inhibitors reduce ischemic brain injury of Wistar rats through decreasing oxidative stress on neurons.

Authors:  Takeshi Hayashi; Keiko Hamakawa; Shoko Nagotani; Guang Jin; Feng Li; Kentaro Deguchi; Yoshihide Sehara; Hanzhe Zhang; Isao Nagano; Mikio Shoji; Koji Abe
Journal:  Brain Res       Date:  2005-03-10       Impact factor: 3.252

5.  Statins induce differentiation and cell death in neurons and astroglia.

Authors:  Pia März; Uwe Otten; André R Miserez
Journal:  Glia       Date:  2007-01-01       Impact factor: 7.452

6.  Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke.

Authors:  Hua Hong; Jin-Sheng Zeng; David L Kreulen; David I Kaufman; Alex F Chen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-06-09       Impact factor: 4.733

7.  Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells.

Authors:  M T Montero; O Hernández; Y Suárez; J Matilla; A J Ferruelo; J Martínez-Botas; D Gómez-Coronado; M A Lasunción
Journal:  Atherosclerosis       Date:  2000-12       Impact factor: 5.162

8.  Reversible middle cerebral artery occlusion without craniectomy in rats.

Authors:  E Z Longa; P R Weinstein; S Carlson; R Cummins
Journal:  Stroke       Date:  1989-01       Impact factor: 7.914

9.  HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells.

Authors:  Wolfgang Dichtl; Jozef Dulak; Matthias Frick; Hannes F Alber; Severin P Schwarzacher; Mikko P S Ares; Jan Nilsson; Otmar Pachinger; Franz Weidinger
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-01-01       Impact factor: 8.311

10.  HMG-CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis.

Authors:  Joachim G Schulz; Julian Bösel; Magali Stoeckel; Dirk Megow; Ulrich Dirnagl; Matthias Endres
Journal:  J Neurochem       Date:  2004-04       Impact factor: 5.372

View more
  4 in total

Review 1.  Regulation of Small GTPase Prenylation in the Nervous System.

Authors:  Jairus M Reddy; Namrata G R Raut; Jennifer L Seifert; DiAnna L Hynds
Journal:  Mol Neurobiol       Date:  2020-01-27       Impact factor: 5.590

2.  HMG-CoA Reductase Inhibitors Attenuate Neuronal Damage by Suppressing Oxygen Glucose Deprivation-Induced Activated Microglial Cells.

Authors:  Dan Lu; Lingling Shen; Hongcheng Mai; Jiankun Zang; Yanfang Liu; Chi-Kwan Tsang; Keshen Li; Anding Xu
Journal:  Neural Plast       Date:  2019-02-17       Impact factor: 3.599

3.  Atorvastatin modulates the expression of aging-related genes in the brain of aging induced by D-galactose in mice.

Authors:  Manijeh Motevalian; Neda Tekyeh Maroof; Mohammad Hadi Nematollahi; Fatemeh Khajehasani; Iman Fatemi
Journal:  Iran J Basic Med Sci       Date:  2021-10       Impact factor: 2.699

4.  Compatibility of ingredients of Danshen (Radix Salviae Miltiorrhizae) and Honghua (Flos Carthami) and their protective effects on cerebral ischemia-reperfusion injury in rats.

Authors:  Haoyu Wan; Yuting Yang; Zhiwei Li; Lan Cheng; Zhishan Ding; Haitong Wan; Jiehong Yang; Huifen Zhou
Journal:  Exp Ther Med       Date:  2021-06-08       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.